Peregrine's Anti-Angiogenesis Antibody, 2C3, Shown to Inhibit Tumor Growth by 75%

Peregrine Pharmaceuticals Reduces Clinical Department

Peregrine To Develop Vascular Targeting Agents (VTA) With Schering AG

Peregrine Announces Quarterly Conference Call

Peregrine's Non-Radiolabeled Lym-1 Antibody Shows Significant Anti-Tumor Effect on B-Cell Lymphoma in Preclinical Studies

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Published In International Journal of Radiation - Oncology - Biology - Physics

Peregrine Pharmaceuticals Receives Orphan Drug Designation For Cotara(TM) In Europe

Avid Bioservices Presents at IBC Biopharmaceutical Production Week Conference

Vascular Targeting Agent Approach to Targeted Therapy Published in The Pharmacogenomics Journal

Peregrine's Anionic Phospholipid Based Vascular Targeting Agent Technology Published in Cancer Research